AbbVie (ABBV): Q1 2026 Earnings in Focus After -8% YTD Decline
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $14.8 billion, reflecting about 11% year-over-year growth driven by immunology drugs.
- Consensus adjusted EPS estimate stands at $2.69, though AbbVie recently guided $2.56–$2.60 after a $744 million IPR&D (intellectual property research and development) charge.
- Skyrizi sales projected at $4.43 billion and Rinvoq at $2.07 billion, key to offsetting Humira's ongoing decline.
- Investors watching for updates on 2026 full-year guidance of $13.96–$14.16 adjusted EPS.
- AbbVie's immunology portfolio remains central amid post-Humira transition.
- Stock trades down about 8% year-to-date, heightening focus on execution.
Earnings Context and Why It Matters
As AbbVie (ABBV) prepares to report Q1 2026 earnings on April 29, this feels like a key milestone in the company's shift away from Humira dominance toward growth from newer immunology drugs like Skyrizi and Rinvoq. With Humira facing biosimilar competition since 2023, AbbVie still delivered record 2025 revenue of $61.2 billion, fueled by more than 32% growth in those star products. From what I see, this report will help investors assess whether the immunology momentum holds up against patent expirations, R&D spending, and competition in a market exceeding $200 billion. Solid numbers here could reinforce AbbVie's position as a dividend aristocrat with a promising pipeline, while any misses could add to volatility in the sector.
Earnings Expectations
Wall Street looks for Q1 2026 net revenue of $14.72–$14.78 billion, up about 11% from Q1 2025, according to Zacks and MarketBeat consensus figures. Adjusted diluted EPS consensus sits at $2.67–$2.70, following the Q4 2025 beat of $2.71. That said, AbbVie recently adjusted its Q1 guidance downward to $2.56–$2.60 due to a $744 million IPR&D charge from acquisitions.
In the immunology segment, expectations center on Skyrizi at $4.43 billion (up ~45% YoY) and Rinvoq at $2.07 billion (up ~60% YoY), based on Zacks estimates, as they work to counter Humira's U.S. decline. I'm paying close attention to operational growth, margin performance, and any pipeline updates in oncology and neuroscience. AbbVie has beaten EPS estimates in the past four quarters, though the stock's response has depended heavily on guidance.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment leans cautiously optimistic, even with the stock down 8% year-to-date amid broader biotech pressures and the recent guidance tweak. Options pricing suggests about 7% volatility after the report. On the bullish side, the immunology portfolio's run-rate now tops $7 billion per quarter; bears, however, point to IPR&D impacts and Humira erosion risks. Looking back, beats with positive guidance have driven +2–5% gains, but margin pressures have led to downside.
Tools I Use: Tickeron’s AI Screener
One resource I turn to regularly in my analysis is Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of names using technical patterns, fundamentals, trends, volatility, and AI signals—customizing by industry, market cap, indicators, price patterns, and performance metrics. In reviewing ABBV, for instance, it helped me quickly spot how it compares to peers on key trends. This streamlines my workflow far beyond manual screening, surfacing trade ideas, breakouts, and opportunities efficiently.
Forward Outlook and Key Factors to Monitor
After Q1 results, the spotlight will turn to whether AbbVie reaffirms or adjusts its full-year 2026 guidance of $13.96–$14.16 adjusted EPS, pointing to ~4–5% growth. If Skyrizi and Rinvoq keep accelerating in psoriasis, Crohn's disease, and emerging indications, revenue could approach the $67 billion consensus.
Pipeline developments to watch include label expansions, Phase 3 readouts in immunology and oncology—like ABBV-383 for multiple myeloma—and M&A progress. I'll be tracking cost discipline with R&D at ~20% of sales and gross margins around 85%, plus international expansion to offset U.S. biosimilar headwinds. In my view, this is important because broader factors like Fed rate decisions, peer earnings from Eli Lilly and Johnson & Johnson, and election-year drug pricing policies could influence the path ahead. Strong execution positions AbbVie for dividend increases and portfolio stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABBV in upward trend: 10-day moving average broke above 50-day moving average on May 20, 2026
The 10-day moving average for ABBV crossed bullishly above the 50-day moving average on May 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ABBV as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on June 23, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 361 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 348 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABBV broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.568). ABBV's P/E Ratio (112.750) is considerably higher than the industry average of (26.482). Projected Growth (PEG Ratio) (0.634) is also within normal values, averaging (15.849). Dividend Yield (0.029) settles around the average of (0.031) among similar stocks. P/S Ratio (6.494) is also within normal values, averaging (3.939).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement